Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
about
Aging and liver diseasePegylated interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C.Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.Treatment Response and Tolerability of Pegylated Interferon-α Plus Ribavirin Combination Therapy in elderly Patients (≥ 65 years) With Chronic Hepatitis C in Korea.Analysis of renal function during telaprevir-based triple therapy for chronic hepatitis CAntiviral Therapy in Elderly Patients With Hepatitis C Virus InfectionPredictors for dose reduction of antiviral therapy in older patients infected with hepatitis C virus: a meta-regression analysis.Chronic hepatitis C in the aged: much ado about nothing or nothing to do?Treating hepatitis C in the elderly: the future is near?Optimal management of patients with chronic hepatitis C and comorbidities.Hepatitis C Infection in the Elderly.Response to peginterferon-alpha 2b and ribavirin in Japanese patients with chronic hepatitis C genotype 1.Interferon- α -Induced Changes to Natural Killer Cells Are Associated with the Treatment Outcomes in Patients with HCV Infections.Predictive value of the IFNL4 polymorphism on outcome of telaprevir, peginterferon, and ribavirin therapy for older patients with genotype 1b chronic hepatitis C.Increase in platelet count based on inosine triphosphatase genotype during interferon beta plus ribavirin combination therapy.Common genetic polymorphism of ITPA gene affects ribavirin-induced anemia and effect of peg-interferon plus ribavirin therapy.Occurrence of hepatocellular carcinoma was not a rare event during and immediately after antiviral treatment in Japanese HCV-positive patients.Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.Occurrence of clinical depression during combination therapy with pegylated interferon alpha or natural human interferon beta plus ribavirin.Impact of ribavirin dose reduction on the efficacy of pegylated interferon plus ribavirin combination therapy for elderly patients infected with genotype 1b and high viral loads.Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C.Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C.Pegylated interferon α-2b plus ribavirin for Japanese chronic hepatitis C patients with normal alanine aminotransferase.
P2860
Q26852595-AF9DC316-17A5-48C8-A783-A9F153756F15Q33948241-9B6198D8-3294-4C44-8C69-AE74E8C58F45Q35783876-ADB3CB05-3CF9-4D34-B966-C1E9BC8F93EDQ36220201-F7653197-13AB-4A0A-AD87-F76011FC7AC3Q36824924-F23F07A2-7156-413D-AE5F-317EAAFC5825Q37130025-22EE2767-2F9C-417C-BB5D-03AA459C20B9Q38160178-5A0DD96E-E4D1-4459-BBE6-E9457974DEFDQ38198992-4078267E-2950-416D-925F-3E638094D4BDQ38243001-80A7BA62-6764-4BA9-A80D-9D585D510BADQ38295819-C4104BFF-CA42-4D8E-AF90-09469FFFB3C5Q38501726-DFFCA602-3ACD-43B0-83C4-105C701925B6Q40707649-0718C2BA-6190-45DB-AD79-CC8F712DF5CAQ42119090-9BE42C33-6610-46BD-8C03-CB06ED3B02A4Q42247557-82C4CA4A-3D05-4EFD-A5BE-9ACB1303EAE2Q42980055-6072EA0F-16B3-468F-ABB0-F1ECECFBBD10Q43036190-FEB72CF6-8A7B-46FD-9B59-F157E225AC0CQ43039523-BBFE9749-A57F-4BB9-975C-A786D816141CQ43042527-DF841911-D8B5-4D1D-9315-33F9C92A6EB5Q48269156-A88FC1E7-BE7B-4736-8099-C204D0B5D584Q50530986-F41CB598-1BAD-4D9D-8216-FFC2756B3BEFQ50550604-2F1600AF-6ECD-46DE-854E-089F5C8C05E3Q50551487-6B85C4DA-5358-4B8C-A7DF-85834FD58A9EQ50554397-9DCE22A0-4DE5-403B-B8A6-2539B458F72D
P2860
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
description
2010 nî lūn-bûn
@nan
2010 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@ast
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@en
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@nl
type
label
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@ast
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@en
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@nl
prefLabel
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@ast
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@en
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@nl
P2093
P2860
P356
P1476
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C
@en
P2093
Eiji Kajiwara
Hideyuki Nomura
Jun Hayashi
Junya Shimono
Kazuhiro Kotoh
Kazuhiro Takahashi
Koichi Azuma
Kyushu University Liver Disease Study Group
Makoto Nakamuta
Mosaburo Kainuma
P2860
P304
P356
10.3748/WJG.V16.I35.4400
P407
P577
2010-09-01T00:00:00Z